Hints and tips:
...That prompted Shionogi in late October to upgrade its annual guidance for domestic sales of Xocova, while it lowered its target for international sales....
...Japanese drugmaker Shionogi has also shown promising results for its oral antiviral, which rapidly cleared the virus in a mainly vaccinated population....
...Sales of a third antiviral made by Japanese pharma company Shionogi are estimated at $0.5bn, down from $2.5bn, because of delays in the approval of the treatment....
...Pfizer is working on a similar drug, as is Japanese drugmaker Shionogi & Co....
...The UK recently selected two antimicrobials — made by Japan’s Shionogi and the US’s Pfizer — to be purchased via this Netflix-style subscription payment model....
.... ©2021 Nikkei Inc. All rights reserved....
...It is made by ViiV Healthcare, a company that is majority-owned by GSK and also backed by Pfizer and Shionogi....
...ViiV Healthcare, the specialist HIV company majority-owned by GSK, with US company Pfizer and Japan’s Shionogi as shareholders, announced the results of a 96-week trial — the most lengthy study so far —...
...Gilead posted total HIV revenue of $12.8bn in 2016, while Viiv has annual revenues of roughly £3.6bn Viiv is a HIV-focused joint venture with Pfizer and Japan’s Shionogi in which GSK has a majority stake...
...In Japan, Takeda Pharmaceutical slid 2.7 per cent, Astellas Pharma fell 3.9 per cent and Shionogi sank 3.7 per cent on Thursday morning, while in Australia biotech company CSL Ltd dropped 1.4 per cent and...
...ViiV Healthcare, which is a joint venture between the UK drugmaker, Pfizer of the US and Japan’s Shionogi, has struck an agreement with the government of Botswana through which patients that have recently...
...GSK has booked a £2bn liability on its balance sheet for the put options that Pfizer and its other partner, Shionogi of Japan, have to sell their ViiV stakes to the UK group....
...It was added to the portfolio of ViiV, and under the terms of a new agreement completed last year to reflect its pivotal role, Shionogi received 10 per cent of the equity in ViiV....
...Plethora Solutions rose 68.9 per cent after it took back worldwide rights from Japanese partner Shionogi to commercialise its flagship drug, a treatment for premature ejaculation due to launch in Europe...
...They are set, following regulatory approval, to change to 78.3 per cent and 11.7 per cent, while Shionogi will take 10 per cent. Shionogi will also receive royalties and dividends on the drug....
...But Shionogi jumped 3.8 per cent to Y1,790 following positive news on an HIV drug developed by the company and GlaxoSmithKline. Mumbai recorded its highest close for 2½ years as steelmakers advanced....
...Generic rivals that challenged Crestor’s exclusivity argued that AstraZeneca and Shionogi of Japan, from which it originally licensed the drug, did not fully disclose earlier and similar inventions in its...
...Shionogi rose 3 per cent to Y1,918 after reports that health authorities had granted it a priority review for its peramivir influenza treatment....
...Shionogi, the drugmaker, managed to buck the general downward trend with a 0.4 per cent gain to Y1,853 after it said Sciele Pharma, its US subsidiary, would buy privately held US pharmaceutical company Victory...
...Japan’s Shionogi and Sciele Pharma of the US announced a $1.1bn deal in September....
...Back in Japan, Shionogi’s shares gained 5.7 per cent to Y1,952 after a local report said the pharmaceuticals company was planning on starting sales of a new influenza treatment next year....
...About 18 per cent of Shionogi’s sales come from overseas markets. The majority of that is from royalty income from AstraZeneca’s sales of Shionogi’s anti-cholesterol drug....
...Osaka-based Shionogi said it would pay $31 per share in cash for the Sciele, a 61% premium on Sciele’s Friday closing price of $19.27....
...Last week’s $1.4bn bid by Osaka-based Shionogi for Sciele Pharma of the US is just the latest in a series of deals by Japanese drugmakers to acquire overseas assets....
...Pharmaceutical group Shionogi was 1.3 per cent stronger at Y1,531 after it raised its dividend forecast for the year to the end of March to Y12 from Y8....
International Edition